Share your thoughts, 1 month free Claude Pro on usSee more
WorkDL logo mark

Progressive Multi-Agent Reasoning for Biological Perturbation Prediction

About

Predicting gene regulation responses to biological perturbations requires reasoning about underlying biological causalities. While large language models (LLMs) show promise for such tasks, they are often overwhelmed by the entangled nature of high-dimensional perturbation results. Moreover, recent works have primarily focused on genetic perturbations in single-cell experiments, leaving bulk-cell chemical perturbations, which is central to drug discovery, largely unexplored. Motivated by this, we present LINCSQA, a novel benchmark for predicting target gene regulation under complex chemical perturbations in bulk-cell environments. We further propose PBio-Agent, a multi-agent framework that integrates difficulty-aware task sequencing with iterative knowledge refinement. Our key insight is that genes affected by the same perturbation share causal structure, allowing confidently predicted genes to contextualize more challenging cases. The framework employs specialized agents enriched with biological knowledge graphs, while a synthesis agent integrates outputs and specialized judges ensure logical coherence. PBio-Agent outperforms existing baselines on both LINCSQA and PerturbQA, enabling even smaller models to predict and explain complex biological processes without additional training.

Hyomin Kim, Sang-Yeon Hwang, Jaechang Lim, Yinhua Piao, Yunhak Oh, Woo Youn Kim, Chanyoung Park, Sungsoo Ahn, Junhyeok Jeon• 2026

Related benchmarks

TaskDatasetResultRank
Gene regulation direction predictionPerturbQA Jurkat
AUROC0.68
18
Gene regulation direction predictionPerturbQA (HepG2)
AUROC0.67
18
Gene regulation direction predictionPerturbQA K562
AUROC0.64
18
Gene regulation direction predictionPerturbQA RPE1
AUROC0.6
18
Gene regulation direction predictionLINCSQA L1000
Accuracy (Bone marrow)0.52
9
Target prioritizationBRAF inhibitor case study A375 cell line, Dabrafenib
Target Rank1
3
Target prioritizationBRAF inhibitor case study A375 cell line, Vemurafenib
Target Rank1
3
Showing 7 of 7 rows

Other info

Follow for update